Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

Liam O'Mahony

doi:10.1111/all.14221

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

Liam O'Mahony

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Allergy: European Journal of Allergy and Clinical Immunology
DOIs	https://doi.org/10.1111/all.14221
Publication status	Published - 24 Feb 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/all.14221

Cite this

@article{a6e83e1309e2449da5dcb934b22f417d,

title = "Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma",

author = "Liam O'Mahony",

year = "2020",

month = feb,

day = "24",

doi = "10.1111/all.14221",

language = "English",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

AU - O'Mahony, Liam

PY - 2020/2/24

Y1 - 2020/2/24

UR - http://dx.doi.org/10.1111/all.14221

U2 - 10.1111/all.14221

DO - 10.1111/all.14221

M3 - Article

SN - 0105-4538

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

ER -

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

UN SDGs

Access to Document

Other files and links

Cite this